Login to Your Account



CHMP Backs Biotie Therapies' Selincro in Alcohol Dependence

By Cormac Sheridan
Staff Writer

Monday, December 17, 2012
Breaking out the champagne may not have been the appropriate reaction, but Biotie Therapies Oyj had reason to celebrate Friday, as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for its alcohol dependence drug Selincro (nalmefene).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription